on Biomind Labs Inc. (CVE:BMND.NE)
Biomind Labs to List on Canadian Securities Exchange
Biomind Labs Inc., a clinical-stage biopharmaceutical company, announced its approval to list common shares on the Canadian Securities Exchange (CSE). Trading is set to begin on August 11, 2026, under the symbol "BMND". This change follows the company's decision to delist from Cboe Canada, effective August 10, 2026.
Shareholders need not take action regarding this transition, as the OTC Pink listing remains unaffected. The company expressed gratitude to Cboe Canada for its support over the past five years. The move to the CSE marks a new chapter for Biomind, aligning with its ongoing business development and investment opportunities.
Biomind continues to focus on neuroscience and biomedical research to create novel pharmaceutical solutions addressing central nervous system conditions. Their strategy emphasizes rigorous clinical validation.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biomind Labs Inc. news